AEON Biopharma (AEON) vs Vyome (HIND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AEON Biopharma (AEON) has outperformed Vyome (HIND) over the past year, losing 66.7% versus a loss of 67.1%. AEON Biopharma is the larger company by market cap ($15.5 million vs $14.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | HIND |
|---|---|---|
| Share price | $0.3113 | $2.04 |
| Market cap | $15.53M | $14.32M |
| 1-day change | +7.44% | -0.97% |
| YTD return | -71.70% | -40.70% |
| 1-year return | -66.71% | -67.15% |
| 5-year return | — | -100.00% |
| P/E ratio (TTM) | — | 1.16 |
| EPS (TTM) | $-4.39 | $1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.45 | $6.56 |
| 52-week low | $0.177 | $1.75 |
| Distance from 52-week high | -78.53% | -68.90% |
| Average volume | 8.67M | 13.64K |
| Shares outstanding | 49.88M | 7.02M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
AEON vs HIND FAQ
Which is bigger, AEON Biopharma or Vyome?
AEON Biopharma (AEON) is larger, with a market capitalization of $15.53M compared with $14.32M for Vyome (HIND).
Which stock has performed better over the past year, AEON or HIND?
AEON returned -66.71% over the past 12 months, compared with -67.15% for HIND (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and Vyome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.